Phase 1 Study of AAV9.LAMP2B Gene Therapy in Danon Disease

In a study involving patients with Danon disease, AAV9.LAMP2B gene therapy appeared to be safe, increased cardiac LAMP2 expression, and was associated with clinical improvement over 24 to 54 months.

​   The New England Journal of Medicine: Search Results in Cardiology